119 related articles for article (PubMed ID: 21912047)
1. Prostate-specific antigen level and risk of bone metastasis in Sudanese patients with prostate cancer.
Khalid KE; Brair AI; Elhaj AM; Ali KE
Saudi J Kidney Dis Transpl; 2011 Sep; 22(5):1041-3. PubMed ID: 21912047
[No Abstract] [Full Text] [Related]
2. Is prostate-specific antigen a reliable marker of bone metastasisin patients with newly diagnosed cancer of the prostate?
Gontero P; Muir GH
Eur Urol; 1998 Dec; 34(6):518-9. PubMed ID: 9831795
[No Abstract] [Full Text] [Related]
3. Correlation between bone metabolic markers and bone scan in prostatic cancer.
Maeda H; Koizumi M; Yoshimura K; Yamauchi T; Kawai T; Ogata E
J Urol; 1997 Feb; 157(2):539-43. PubMed ID: 8996351
[TBL] [Abstract][Full Text] [Related]
4. High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer.
Furuya Y; Cho S; Ohta S; Sato N; Kotake T; Masai M
J Urol; 2001 Jul; 166(1):213. PubMed ID: 11435864
[No Abstract] [Full Text] [Related]
5. Undetectable prostate specific antigen in disseminated prostate cancer.
Beardo P; Fernández PL; Corral JM; Filella X; Alcover J
J Urol; 2001 Sep; 166(3):993. PubMed ID: 11490269
[No Abstract] [Full Text] [Related]
6. Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.
Loeb S; Makarov DV; Schaeffer EM; Humphreys EB; Walsh PC
J Urol; 2010 Jul; 184(1):157-61. PubMed ID: 20483148
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in metastatic prostate cancer.
Yigitbasi O; Ozturk U; Goktug HN; Gucuk A; Bakirtas H
Urol Oncol; 2011; 29(2):162-5. PubMed ID: 19450995
[TBL] [Abstract][Full Text] [Related]
8. [Is it possible to do without bone gammagraphy in the staging of prostatic cancer?].
Ruiz de la Roja JC; Llorente Abarca C; Romero Cagigal I; Páez Borda A; Fernández González I; Martín Osés E; Berenguer Sánchez A
Actas Urol Esp; 1995 Feb; 19(2):123-7. PubMed ID: 7539572
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan.
Ishizuka O; Tanabe T; Nakayama T; Kawakami M; Kinebuchi Y; Nishizawa O
Int J Urol; 2005 Aug; 12(8):728-32. PubMed ID: 16174046
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer metastasizing to bone with normal PSA level: a lesson to learn.
Kumar P; Pati J
Hosp Med; 2005 Apr; 66(4):244. PubMed ID: 15889877
[No Abstract] [Full Text] [Related]
11. Bone scan in initial staging of prostate cancer.
Boughattas S; Letaief B; Hassine H; Chatti K; Essabah H
Tunis Med; 2003 Jun; 81(6):400-6. PubMed ID: 14534946
[TBL] [Abstract][Full Text] [Related]
12. [Impact of specific prostatic antigen on the rationalization of the use of bone gammagraphies in the follow-up of hormone-treated non- metastatic prostatic cancer].
Morote Robles J; Reig Ruiz C; Vila Barja J; López Pacios MA; de Torres Mateos JA; Soler Roselló A
Actas Urol Esp; 1993 May; 17(5):292-4. PubMed ID: 7688176
[TBL] [Abstract][Full Text] [Related]
13. Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: feasibility in Asian population.
Lai MH; Luk WH; Chan JC
Urol Oncol; 2011; 29(3):275-9. PubMed ID: 19734069
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
Kageyama Y; Kihara K; Kamata S; Nagahama K; Yonese J; Fukuda H; Tosaka A; Nagamatsu H; Ishizaka K; Tsujii T; Kitahara S; Morita T; Oshima H
Hinyokika Kiyo; 1996 Mar; 42(3):197-9. PubMed ID: 8619388
[TBL] [Abstract][Full Text] [Related]
15. [Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer].
Wang ZL; Wang XF
Zhonghua Nan Ke Xue; 2005 Nov; 11(11):825-7. PubMed ID: 16333960
[TBL] [Abstract][Full Text] [Related]
16. Preserved value of bone scintigraphy for the detection of skeletal metastases in prostate cancer patients with low prostate-specific antigen levels: effect of hormonal therapy and poor histologic differentiation.
Caglar M; Tuncel M
Clin Nucl Med; 2002 Jul; 27(7):532-3. PubMed ID: 12072787
[No Abstract] [Full Text] [Related]
17. Premature conclusions may harm good ideas.
Staudenherz A; Sinzinger H
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):625-6; author reply 627. PubMed ID: 15723225
[No Abstract] [Full Text] [Related]
18. Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database.
Sourbeer KN; Howard LE; Moreira DM; Amarasekara HS; Chow LD; Cockrell DC; Hanyok BT; Pratson CL; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Hernandez RK; Freedland SJ
J Urol; 2015 Apr; 193(4):1232-8. PubMed ID: 25463986
[TBL] [Abstract][Full Text] [Related]
19. Metastatic prostate cancer with a normal prostate-specific antigen level.
Ruiz-Martín I; Rodríguez-Sánchez CA; Ocaña-Fernández A; del Valle-Zapico J; Soto de Prado-Otero D; Cruz-Hernández JJ
Clin Transl Oncol; 2005 Oct; 7(9):412-3. PubMed ID: 16238977
[TBL] [Abstract][Full Text] [Related]
20. Bone scanning--who needs it among patients with newly diagnosed prostate cancer?
Hirobe M; Takahashi A; Hisasue S; Kitamura H; Kunishima Y; Masumori N; Iwasawa A; Fujimori K; Hasegawa T; Tsukamoto T
Jpn J Clin Oncol; 2007 Oct; 37(10):788-92. PubMed ID: 17911377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
